Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 39-47

  Doran, Derek E ^a   Weiss, Daiana ^a   Zhang, Yong ^a   Griendling, Kathy K ^a   Taylor, W Robert ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin II receptor antagonists; Atherosclerosis; Oxidative stress; Vascular biology

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INJURY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME SYNTHESIS; GENE EXPRESSION; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANIMAL; AORTA; DISEASE MODEL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; PATHOLOGY;

AMLODIPINE; ANIMALS; AORTA; ATHEROSCLEROSIS; BENZIMIDAZOLES; CALCIUM CHANNELS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYDROGEN PEROXIDE; INFLAMMATION; MICE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 34250208256     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.11.030     Document Type: Article

References (56)

1. Weiss D., Sorescu D., and Taylor W.R. Angiotensin II and atherosclerosis. Am J Cardiol 87 (2001) 25C-32C
2. Weiss D., Kools J.J., and Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103 (2001) 448-454
3. Daugherty A., and Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 892 (1999) 108-118
4. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 (2000) 1605-1612
5. Ihara M., Urata H., Kinoshita A., et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33 (1999) 1399-1405
6. Ushio-Fukai M., Alexander R.W., Akers M., and Griendling K.K. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273 (1998) 15022-15029
7. Candido R., Jandeleit-Dahm K.A., Cao Z., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 (2002) 246-253
8. Miyazaki M., Sakonjo H., and Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol 128 (1999) 523-529
9. Lee M.A., Bohm M., Paul M., and Ganten D. Tissue rennin-angiotensin systems. Their role in cardiovascular disease. Circulation 87 (1993) IV7-13
10. Dzau V.J. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
11. Gibbons G.H. The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Am J Hypertens 11 (1998) 177S-181S
12. Prasad A., Tupas-Habib T., Schenke W.H., et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 101 (2000) 2349-2354
13. da Cunha V., Tham D.M., Martin-McNulty B., et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178 (2005) 9-17
14. Griendling K.K., Ushio-Fukai M., Lassegue B., and Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29 (1997) 366-373
15. Griendling K.K., and Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91 (2000) 21-27
16. Taylor W.R. Mechanical deformation of the arterial wall in hypertension: a mechanism for vascular pathology. Am J Med Sci 316 (1998) 156-161
17. Li-Saw-Hee F.L., Edmunds E., Blann A.D., Beevers D.G., and Lip G.Y. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75 (2000) 43-47
18. Capers Q.t., Alexander R.W., Lou P., et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 30 (1997) 1397-1402
19. Capers Q.t., Laursen J.B., Fukui T., et al. Vascular thrombin receptor regulation in hypertensive rats. Circ Res 80 (1997) 838-844
20. Brunner H.R., Laragh J.H., Baer L., et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286 (1972) 441-449
21. Schuh J.R., Blehm D.J., Frierdich G.E., McMahon E.G., and Blaine E.H. Differential effects of rennin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91 (1993) 1453-1458
22. Andersson R.G., Jacobsson L., and Persson K. Angiotensin converting enzyme inhibitors and atherosclerosis. J Physiol Pharmacol 45 (1994) 13-25
23. Kowala M.C., Grove R.I., and Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 108 (1994) 61-72
24. Chobanian A.V., Hope S., and Brecher P. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension 25 (1995) 1306-1310
25. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
26. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
27. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
28. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
29. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
30. Warnholtz A., Nickenig G., Schulz E., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the rennin-angiotensin system. Circulation 99 (1999) 2027-2033
31. Dawson T.C., Kuziel W.A., Osahar T.A., and Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143 (1999) 205-211
32. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
33. Griendling K.K., and Alexander R.W. The angiotensin (AT1) receptor. Semin Nephrol 13 (1993) 558-566
34. Griendling K.K., Lassegue B., and Alexander R.W. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 36 (1996) 281-306
35. Griendling K.K., and Alexander R.W. Oxidative stress and cardiovascular disease. Circulation 96 (1997) 3264-3265
36. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
37. Hayek T., Attias J., Coleman R., et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 44 (1999) 579-587
38. Hayek T., Attias J., Smith J., Breslow J.L., and Keidar S. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 31 (1998) 540-544
39. Keidar S., Attias J., Coleman R., et al. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol 35 (2000) 64-72
40. Chobanian A.V., Haudenschild C.C., Nickerson C., and Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 20 (1992) 473-477
41. Miyazaki M., and Takai S. Antiatherosclerotic effect of alacepril, an angiotensin-converting enzyme inhibitor, in monkeys fed a high-cholesterol diet. Hypertens Res 22 (1999) 49-54
42. Overturf M., Sybers H., Schaper J., and Taegtmeyer H. Hypertension and atherosclerosis in cholesterol-fed rabbits. II. One-kidney, one clip Goldblatt hypertension treated with nifedipine. Atherosclerosis 66 (1987) 63-76
43. Kritchevsky D., Tepper S.A., and Klurfeld D.M. Flordipine, a calcium channel blocker, which does not influence lipidemia or atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 69 (1988) 89-92
44. Waters D., Lesperance J., Francetich M., et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82 (1990) 1940-1953
45. Watanabe N., Ishikawa Y., Okamoto R., Watanabe Y., and Fukuzaki H. Nifedipine suppressed atherosclerosis in cholesterol-fed rabbits but not in Watanabe heritable hyperlipidemic rabbits. Artery 14 (1987) 283-294
46. Thiery J., Niedmann P.D., and Seidel D. The beneficial influence of nifedipine on the regression of the cholesterol-induced atherosclerosis in rabbits. Res Exp Med (Berl) 187 (1987) 359-367
47. van de Poll S.W., Delsing D.J., Jukema J.W., et al. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 164 (2002) 65-71
48. Franzoni F., Santoro G., Regoli F., et al. An in vitro study of the peroxyl and hydroxyl radical scavenging capacity of the calcium antagonist amlodipine. Biomed Pharmacother 58 (2004) 423-426
49. Mason R.P., Marche P., and Hintze T.H. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 23 (2003) 2155-2163
50. Turgan N., Habif S., Kabaroglu C.G., et al. Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits. J Biomed Sci 10 (2003) 65-72
51. Tipping P.G., Davenport P., Gallicchio M., et al. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol 143 (1993) 875-885
52. Vaughan D.E., Lazos S.A., and Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the rennin-angiotensin system and thrombosis. J Clin Invest 95 (1995) 995-1001
53. Vaughan D.E. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 87 (2001) 18C-24C
54. 2. Hypertension 46 (2005) 732-737
55. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 32 (1998) 488-495
56. Chen J., Liu Y., Liu H., Hermonat P.L., and Mehta J.L. Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler Thromb Vasc Biol 26 (2006) 1163-1168